Maria Re to Viral Load
This is a "connection" page, showing publications Maria Re has written about Viral Load.
Connection Strength
0.321
-
Impact of Different Antiretroviral Strategies on Total HIV-DNA Level in Virologically Suppressed HIV-1 Infected Patients. Curr HIV Res. 2017; 15(6):448-455.
Score: 0.151
-
Simplification to dual-therapy containing lamivudine and darunavir/ritonavir or atazanavir/ritonavir in HIV-infected patients on virologically suppressive antiretroviral therapy. Infect Dis (Lond). 2018 05; 50(5):352-360.
Score: 0.040
-
Evaluation of HIV-DNA and inflammatory markers in HIV-infected individuals with different viral load patterns. BMC Infect Dis. 2017 08 22; 17(1):581.
Score: 0.040
-
Prevalence of R5 strains in multi-treated HIV subjects and impact of new regimens including maraviroc in a selected group of patients with CCR5-tropic HIV-1 infection. Int J Infect Dis. 2013 Oct; 17(10):e875-82.
Score: 0.029
-
Meaning of DNA detection during the follow-up of HIV-1 infected patients: a brief review. New Microbiol. 2006 Apr; 29(2):81-8.
Score: 0.018
-
Antiviral activity of interferon-based combination therapy in critically ill patients with COVID-19: Preliminary observations. J Glob Antimicrob Resist. 2021 03; 24:124-126.
Score: 0.012
-
Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial. PLoS One. 2017; 12(11):e0187393.
Score: 0.010
-
Monitoring the treatment of hepatitis C with directly acting antivirals by serological and molecular methods. PLoS One. 2017; 12(11):e0187755.
Score: 0.010
-
Substitution of nevirapine or raltegravir for protease inhibitor vs. rosuvastatin treatment for the management of dyslipidaemia in HIV-infected patients on stable antiretroviral therapy (Nevrast study). Infect Dis (Lond). 2017 Oct; 49(10):737-747.
Score: 0.010